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Sunmmar Soluble cytokeratin fragment 19 levels were measured with an enzyme immunoassay method
developed by Boehringer Mannheim (Enzymun-Test CYFRA 21-1) in the serum of 185 patients with lung
cancer [149 with non-small-cell lung cancer (NSCLC) and 36 with small-cell lung cancer (SCLC)] and 97
patients with benign lung diseases in order to determine its clinical usefulness in the diagnosis of lung cancer
and follow-up of treatment. We used the cut-off value of 3.5 ng ml'. established by the Japan CYFRA
research group. This cut-off value is based on calculations using the receiver operating characteristic approach
instead of using the 95% specificity approach recommended by other authors. The resulting sensitivity and
specificity for the group of all lung cancer patients were 65.4% and 84.5% respectively. The sensitivity was
highest (76.1%) for squamous cell carcinoma and lowest (44.4%) for SCLC. For NSCLC patients, when
CYFRA 21-1 levels were analysed by node (N) factor, patients who presented with mediastinal lymph node
metastasis (N2 or N3) demonstrated higher serum CYFRA 21-1 levels (5.6; interquartile range
3.2-11.5ng ml-1) than patients without mediastinal node metastasis (NO or Nl, 3.9; interquartile range
2.2-10.0 ng ml-; Mann-Whitney UI-test, P = 0.0373). We compared the discriminatory power of CYFRA
21-1 with that of other tumour markers including carcinoembryonic antigen (CEA), squamous cell carcinoma
antigen (SCC) and neuron-specific enolase (NSE). The area under the curve (AUC) of each ROC curve was
calculated using the CLABROC program for statistical analysis. CYFRA 21-1 appeared to have the most
discriminatory power of the markers tested in the diagnosis of lung cancer. In serial measurements of 14
patients receiving chemotherapy or radiotherapy, a high degree of correlation was noted between serum levels
of CYFRA 21-1 and extent of clinical response (Wilcoxon, P= 0.0093).
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Lung cancer is the commonest cause of death due to cancer
in the world. Since non-small-cell lung cancer (NSCLC)
accounts for the majority (70-80%) of all lung cancers,
improvement in its treatment will have a major impact on
both the rate of survival of lung cancer patients and the rate
of survival of all cancer patients as a group. In contrast to
other solid tumours, adequate assessment of follow-up and
efficiency of therapy exists only for small-cell lung cancer
(SCLC) by means of the determination of neuron-specific
enolase (NSE) (Carney et al., 1982; Akoun et al., 1985).
None of the several serum components proposed as
indicators of the extent of disease and clinical response to
treatment appear to be sensitive or specific enough for
general use in the management of the patients with NSCLC
or as screening tools for early detection of disease.
All epithelial tissues, both normal and malignant (Moll et
al., 1982; Osborn and Weber, 1982), contain cytokeratins,
which form the intermediate filament cytoskeleton within
epithelial cells. This family of human cytokeratins consists of
19 different polypeptides, which have been numbered 1-19
by Moll et al. (1982). These cytokeratins are not randomly
distributed in the various epithelia, but appear to be charac-
teristic for certain types of epithelial differentiation (Hoefler
and Denk, 1984). Cytokeratin 19 is an acidic (type I) subunit
expressed in all simple epithelia and in carcinomas such as
lung cancer which arise from them (Broers et al., 1987, 1988).
A fragment of cytokeratin subunit 19 can be measured in
serum with a new enzyme immunoassay using two mouse
MAb, Ks 19.1 and BM 19.21 (Bodenmuller et al., 1992). This
cytokeratin 19 fragment is referred to as CYFRA 21-1. The
present study was undertaken to identify relationships
between levels of this marker and other clinically significant
vanables in patients with SCLC and NSCLC, and also to
determine the usefulness of CYFRA 21-1 as a marker for
follow-up in the treatment of lung cancer.
Materials and methods
Patients
This study was performed retrospectively using 185 con-
secutively obtained samples (Table I) of frozen serum stored
at - 80C. All patients from whom samples were obtained
had been referred to the Osaka Prefectural Habikino Hos-
pital between July 1991 and February 1993 and had his-
tologically confirmed lung cancer. The patient population
included 36 with small-cell lung cancer (SCLC) and 149 with
non-small-cell lung cancer (NSCLC); of the latter, 65 had
adenocarcinoma, 67 squamous cell carcinoma and 17 large-
cell carcinoma. The performance status was rated using the
Eastern Cooperative Oncology Group cnrtenra. Patients were
staged by routine chest radiography computerised tomo-
graphy of the chest, brain and upper abdomen, fibre-optic
bronchoscopy and bone scanning. The staging procedures
were those of the tumour-node-metastasis system (Moun-
tain, 1986). Staging of NSCLC was performed using Moun-
tain's stage grouping method. For SCLC, limited disease was
defined as that confined to one hemithorax including medias-
tinal lymph nodes and/or ipsilateral supraclavicular lymph
nodes, while extensive disease was defined as that more
advanced than limited SCLC.
Control
Control blood samples were obtained from 97 patients refer-
red to the Habikino Hospital for a variety of non-malignant
lung diseases (Table I). These patients were diagnosed using
clinical, radiological and laboratory criteria.
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Tabe I Patient charactristics
No. of patients
Male/female
median age (range)
OS 0,1/2-4
Histology
NSCLC
Adenocarcinoma
Squamous
Large
SCLC
Stage
NSCLC
I,II
IIIA
IIIB
IV
SCLC
Limited disease
Extensive disease
Lung cancer
185
145/40
55 (32-87)
127/58
65
67
17
36
Benign hmg diseae
97
64/33
63 (19-88)
COPD
Tuberculosis
Asthma
Pneumonia
Others
19
33
20
5
20
31
29
44
45
17
19
Squamous, squamous cell arcinoma; Large, large-cell carcinoma;
COPD, chronic obstnutive pulmonary disease.
CYFRA 21-1 and CEA levels at diagnosis and at initial
response to treatment
Serum CYFRA 21-1 and CEA were measured serially (mon-
thly) in 14 patients (five with adenocarcinoma, four with
squamous carcinoma, one with large-ell carcinoma and four
with SCLC) after the start of the first treatment at the time
of the primary diagnosis. These patients were treated with
combination chemotherapy or with chemoradiotherapy.
Their responses were classified using the World Health
Organization (WHO) criteria (Miller et al., 1981) during
mgular meetings.
CYFRA 21-1 enzyme immunoassay
The enzyme immunoassay kit used in our study was
Enzymun-Test CYFRA 21-1 (Boehringer Mannheim, Mann-
heim, Germany). The test is a two-step sandwich assay using
the streptavidin-biotin technology. The test is performed at
25YC using the fully automated ES 300 and ES 600 systems
(Boehringer Mannheim). A blood sample was taken from
each patient at presentation, and the serum was separated
and stored at - 80-C until tested. Standard or sample, 35 sl
in volume, and incubation solution, 700MI in volume,
together with biotinylated antibody (Ks 19.1) were incubated
in streptavidin-coated polystyrene tubes for 30 mm. After
aspiration and washing, 700ILI of incubation solution
together with antibody-horseradish peroxidase (HRP) con-
jugate (BM 19.21) was added. After another 30 min incuba-
tion period, the tubes were again aspirated and washed.
Finally, 700#I of 2,2'-a7ino-bis(3-ethylbenzothiazoine-6-
sulphonate) (ABTS) substrate solution was added and the
mixture incubated for 60min. Absorbance was read at
422nm and the CYFRA 21-1 concentration was alculated
from the standard curve. All serum samples were assayed
blindly, without clinical information.
Statistics
Data are given as the median and the 90th and 75th percen-
ties of marker levels. Except for ROC, data were analysed
with non-parametric methods. The Mann-Whitney U-test
was used for comparison of two groups of random samples.
Multiple comparison testng was performed by Krus-
kal-Wallis one-way analysis. To compare the accuracies of
two different markers, the areas under their ROC curves were
compared by univariate z-score testng with the CLABROC
program (Metz, 1991). The Wilcoxon single-rani test was
used to compare the levels of markers before and during
treatment. Differences were considered significant when P-
values <0.05 were obtained.
The ROC curves, which correlate true and false-positive
rate [sensitivity and (I- specificity)], were constructed using
the CLABROC program (Metz, 1991) in an attempt to com-
pare the accuracies of various markers. In addition, we cal-
culated the area under the curve (AUC) for each marker and
analysed these using the same program. The program cal-
culates maximum likelihood estimates of the parameters of a
'bivariate binormal' model for continuously distributed data
from two potentially correlated diagnostic tests, and thus
estimates the binormal ROC curves obtainable with the data
and their correlation and also calculates the statistical
significae of differences between the two areas under the
ROC curves using a univanrate z-score test. The CLABROC
algorithm, developed by CE Metz at the Univesity of
Chicago, is a version of the CORROC algorithm (Metz et
al., 1984) that has been modified to analyse continuously
distributed data (Metz et al., 1990).
Rests
Cut-offvahle calculation
A total of 185 patients with lung cancer and 97 patienps with
benign lung disease were tested for their CYFRA 21-1 level.
The lung cancer group contained 149 patients suffering from
NSCLC.
These data were analysed regarding optimal cut-off selec-
tion from two different viewpoints. First, a cut-off level of
S.Sngml'- - derived from 95% specificity in the benign
group (Klapdor, 1992) was used; the resulting sensitivity is
shown in Table II.
Alternatively, we applied the cut-off level definition recom-
mended by the Japan CYFRA research group (Kawai et a?.,
1993), using the ROC curve approach. The Japan CYFRA
research group choose 3.5 ngml-' as the cut-off because this
level was closest to the upper left-hand corner of the ROC
curve. This level is regarded as optimum in terms of making
the fewest mistakes when prevalence is at or around 50%
(Sackett et al., 1991). In the case of the Japan CYFRA
research group, the prevalenc was 54%. The results for
sensitivity based on a cut-off level of 3.5ngml-' and
spificity are shown in Table H. By using the cut-off
definition based on the ROC curve (3.5 ngml-'), a higher
number of NSCLCs can be detected than when using the
definition based on 95% specificity (5.5 ngml-'). The result-
ing decrase in specificity from 95% to 84.5% when
3.5 ngml' was used as the cut-off was accepted by the
research group, because the main aim of the CYFRA 21-1
test is the early detection of NSCLC. Therefore, in the
following, we focus on the cut-off level of 3.5 ngml-' based
on the ROC approach.
CYFRA 21-1 distribution andhistological type ofhlng cancer
The median and interquartile ranges of serum CYFRA 21-1
values were significantly higher in cancer patients (respec-
tively 4.9 and 2.7-10.7) than in control subjects (2.0 and
1.6-2.9; Mann-Whitney U test, P = 0.0001). As shown
above, the sensitivity and specificity for the group ofall lung
cancer patients were 65.4% and 84.5% respectively, if a
cut-off level of 3.5 ng ml-' was applied. The prevalence of
elevated CYFRA 21-1 levels and the distribution of individ-
ual CYFRA 21-1 values are shown in Figure 1. The median
Table I Comparison of cut-off values, sensitivity and specificity
Cut-off vahw
Speciicity/sensitivity 35ngml' 5-5ngml-'
Specficity (n = 97) 84.5% 95%
Sensitivity for al lung patients 65.4% 45.9%
(n= 185)
Sensitivity for NSCLC (n = 149) 70.5% 51%
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(interquartile range) serum CYFRA 21-1 levels for adenocar-
cinoma. squamous cell carcinoma, large-cell carcinoma and
SCLC patients were 4.8 (2.6-10.0). 7.2 (3.7-17.9), 4.5
(2.7-7.9) and 3.3 (2.3-5.4)ngmln-' respectively. The serum
CYFRA 21-1 level differed by histological type of lung
cancer (Kruskal-Wallis test, P=0.0015). Both the level of
CYFRA 21-1 and the frequency of increased levels were
significantly higher in patients with squamous cell carcinoma
than in patients with adenocarcinoma or SCLC
(Mann-Whitney U-test, P = 0.0251 and 0.0002 respectively).
CYFRA 21-1 and clinical variables at presentation
For patients with NSCLC. CYFRA 21-1 levels were com-
pared according to the stage of disease (Figure 2). Median
(interquartile range) serum CYFRA 21-1 levels were 4.1
(2.0-10.4). 6.3 (3.3-10.6). 6.9 (2.8-16.3) and 6.5 (4.0-14.0)
ng ml-' for stage I II. IIIA, IIIB and IV disease respectively.
A tendency towards an increase in the serum level and
frequency was observed from stage I II to IV, but was not
significant (Kruskal-Wallis test. P = 0.3537). Thirty-one
patients were considered to have clinical stage I and II
disease. Eighteen of these patients (58.1%) were positive for
CYFRA 21-1.
When CYRA 21-1 was analysed by N factor (Figure 3).
the serum levels differed significantly according to nodal
status from NO to N3 (Kruskal-Wallis test, P = 0.0023). In
addition, patients who presented with mediastinal lymph
node metastasis (N2 or N3) demonstrated higher serum
CYFRA 21-1 levels (5.6; interquartile range
3.2-11.5 ng ml-') than patients without mediastinal node
metastasis (NO or N1. 3.9; interquartile range
2.2- 10.0 ng ml-l; Mann-Whitney U-test, P = 0.0373). For
patients with SCLC. no significant difference in CYFRA 21-1
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Figre 1 Distribution of individual serum CYFRA 21-1 values
in patients with lung cancer and non-malignant lung diseases.
Data are presented as upper and lower quartile and range (box).
median value (horizontal line) and the middle 90% distribution
(whisker line). The dashed line indicates the cut-off level of
CYFRA 21-1 of 3.5 ngml-'.
1000 Kruskal - Wallis P= 0.3537
levels was noted between those With limited disease (3.1:
interquartile range 2.2-5.5 ng ml-') and those with extensive
disease (3.9; 2.7-5.3ngml-': Mann-Whitney U-test.
P= 0.07755. Figure 1).
Sensitivities and specificities ofCYFRA 21-1 and other tumour
markers
To examine the clinical potential of CYFRA 21-1. we com-
pared the sensitivity and specificity of three other tumour
marker tests, CEA (RIA; Dainabot. Japan; Matsuoka et al..
1983). SCC (EIA, Dainabot, Japan; Kato and Torigoe, 1977)
and NSE (RIA, Eiken. Japan; Notomi et al.. 1985). with
CYFRA 21-1 using our patient samples. Table III shows the
results for sensitivity if the cut-off is selected according to the
95% specificity approach. as recommended by the 'Ham-
burger group for the Standardization of Tumour Markers'
(Klapdor, 1992). According to this calculation, the sensitivity
of CYFRA 21-1 for both the group of all lung canoer
patients and the group with NSCLC was highest.
Area under ROC curvesfor the various tumour markers
ROC curves for the various tumour markers for the group of
all patients with lung cancer and those with NSCLC are
illustrated in Figures 4 and 5. For the group of all patients.
the areas under the ROC curves were 0.7937 ± 0.0263.
0.7747 ± 0.0287, 0.7217 ± 0.0310 and 0.6243 ± 0.0335 for
CYFRA 21-1. CEA. NSE and SCC respectively. There were
significant differences between the AUC of CYFRA 21-1 on
the one hand and NSE (P = 0.0180) and SCC (P =0.0001)
on the other, but there was no significant difference between
the AUC of CYFRA 21-1 and CEA (P = 0.2926).
For patients with NSCLC, areas under the ROC curves
were 0.8180 ± 0.0267, 0.7875 ± 0.0286, 0.7033 ± 0.0334 and
0.6642 ± 0.0342, for CYFRA 21-1. CEA. NSE and SCC
respectively. The same trends as for the group of all patients
were recognized regarding the significance of difference in
areas under ROC curves between the various markers:
CYFRA 21-1 vs CEA. P = 0.2090; vs NSE. P = 0.0006; vs
SCC. P=0.0001.
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Figure 2 Distnrbution of individual serum CYFRA 21-1 values
according to stage.
Fgre 3 Distribution of individual serum CYFRA 21-1 values
according to N factor in NSCLC.
Table 1II Sensitivit) and specificity (9500 cut-off level) of vanrous
tumour markers
Cut-off Sensitivity- (%)
Marker (n = 97} Lung cancer NSCLC
CYFRA 21-1 5.5 ngml' 51.0 49.5
CEA 4.2 ng ml- 38.2 37.5
SCC 1.9 ngml-' 18.7 26.9
NSE 12.7 ng ml- 32.2 27.2
NSCLC, non-small-cell lung cancer. The cut-offvalues for the four
tumour markers were calculated in 97 patients with benign lung
disease in this study.
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0.7937+0.0263
0.7747 ± 0.0287
0.7217 ± 0.0310
0.6243 ± 0.0335
P= 0.2926
P= 0.0180
P= 0.0001
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Fire 4 Receiver operating characteristics (ROC) curves in
patients with all types of lung cancer and patients with benign
lung disease were constructed using the CLABROC program. *,
CYFRA; 0, CEA: E. NSE; A, SCC.
CYFRA 21-1
c
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-
0._ o
CD
YFRA21-1 0.8180±000267
EA 0.7875±0.0286
SE 0.7033±0.0334
CC 0.6642±0.0342
1 vs CEA P0--2090
NSE P=0.0006
scc P=0.0001
False-positive fraction
Figwe 5 Receiver operating characteristics (ROC) curves in
patients with NCSLC and benign lung disease were constructed
using the CLABROC program. For key, see legend to Figure 4.
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Figure 6 Changes in CYFRA
progressive disease.
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Changes in CYFRA 21-1 and CEA levels during treatment
Determination of CYFRA 21-1 and CEA was performed
serially (monthly) after the initial treatment in 14 patients
(Figure 6). Of ten patients who responded to treatment (six
to chemotherapy, four to chemoradiotherapy), nine had re-
markably large decreases in CYFRA 21-1 levels after the
treatment (4-8 weeks) (Wilcoxon test, P = 0.0093), whereas
CEA levels showed only a small decrease in five patients
(Wilcoxon test, P = 0.4652). In the four patients who did not
respond to treatment, there were no clear decreases in either
CYFRA 21-1 level (Wilcoxon test, P = 0.7213) or CEA level
(Wilcoxon test, P = 0.715). CYFRA 21-1 was measured in
two of the 10 patients who responded to treatment, one at
the first week after treatment and one at the second week.
Their CYFRA 21-1 was reduced from 4.6 to 3.6ngml-' and
from 4.6 to 2.1 ng ml-' respectively.
DEscsson
A variety of substances produced by or associated with
malignancies. including several polypeptide hormones,
placental enzymes and tumour associated antigens, are refer-
red to as tumour markers because their detection in blood or
other body fluids may indicate the presence of tumour.
Although cytokeratins are part of the cytoskeleton, some
cytokeratin fragments may be released into the serum as a
result of cell lysis or tumour necrosis; this is the rationale for
the attempt described here to characterise cytokeratin subunit
19 fragment as a marker for lung cancer. Interestingly, the
expression of cytokeratins is not lost by epithelial cells during
malignant transformation (Moll et al., 1982; Osborn and
Weber 1982), in contrast with the well-known phenotypic
instability of cancer cells (Nicolson, 1987). Antibodies raised
against some antigenic deterninations common to all
cytokeratins are, therefore, useful in typing poorly
differentiated malignant tumours (Osborn and Weber, 1982).
In our series, increased CYFRA 21-1 levels were detected
at diagnosis in 65.4% of all patients with lung cancer, if a
cut-off level of 3.5ngml-' was applied. The median (inter-
quartile range) of serum CYFRA 21-1 was 4.9 (2.7-10.7).
These values are similar to those reported by other inves-
tigators. Elevated levels of CYFRA 21-1 were detected by
Pujol et al. (1989) in 52% of a group of 165 patients with
lung cancer who were studied prospectively. Their median
values were 4.3 ng ml-' with a interquartile range of 2.3-9.5.
In three studies, elevated levels of CYFRA 21-1 were
detected in 60.9% (Ebert et al., 1993), 47% (Stieber et al.,
1993) and 40% (Gaast et al., 1994) of patients with lung
cancer.
A correlation was found between the degree of elevation of
CYFRA 21-1 and the histological type of lung cancer. App-
roximately 40% of patients with SCLC were positive for
CYFRA 21-1, while approximately 70% of those with
NSCLC tested positive. The sensitivity of CYFRA 21-1 was
highest for patients with squamous cell carcinoma. Similar
trends have been reported by other investigators (Ebert et al.,
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1993: Stieber et al.. 1993: Gaast et al.. 1994). These findings
suggest that CYFRA 21-1 should be a useful marker for
NSCLC.
In our patients. a tendency towards an increase in the
serum level and frequency was observed from stage I,II to
IV. In addition, patients with mediastinal lymph node metas-
tases (N2.N3) had higher CYFRA 21-1 levels than did the
patients without mediastinal metastasis. Pujol et at. (1993)
also observed a significant increase in the serum level of
CYFRA 21-1 with stage of disease from I II to IV and noted
that patients who presented with mediastinal lymph node
metastasis had higher serum CYFRA 21-1 levels than those
without it. These findings suggest that CYFRA 21-1 levels
might reflect the tumour burden. Thus, patients who present
with a higher serum CYFRA 21-1 level may require careful
search for mediastinal lymph node and distant metastases.
Moreover, the high incidence of high serum CYFRA 21-1
levels in the group with stage I-II disease clearly indicates
that this marker is of help in screening for early diagnosis of
lung cancer. Contrary to this suggestion. Pujol et al. (1993)
reported that this marker was not useful because of the low
incidence in the stage I-II.
When two or more tests are available for use in diagnosis.
the comparison of ROC curves will often reveal which is
most advantageous. The diagnostic test with the ROC curve
enclosing (below and to the right) the largest area is most
accurate. A comparison of the ROC curves for CYFRA
21-1. CEA. NSE and SCC showed that CYFRA 21-1 was a
better tumour marker for the diagnosis of lung cancer than
NSE and SCC. and showed a modest advantage over CEA.
Other investigators (Ebert et al., 1993; Pujol et al., 1993:
Stieber et al.. 1993) have also noted that the high degree of
specificity and sensitivity of CYFRA 21-1 for diagnosis of
lung cancer is illustrated by ROC curve findings. In these
three studies the ROC curves were very similar to ours. In
addition. Pujol et al. (1993) demonstrated that the area under
the ROC curves for NSCLC was 0.80 ± 0.03. which is com-
patible with our result of 0.8180 ± 0.0267. These findings are
in good agreement with our data.
A higher degree of correlation was found between clinical
response and serial measurements of serum CYFRA 21-1
than for measurements of CEA in patients receiving
cytotoxic therapy for lung cancer. This suggests that the
determination of serum CYFRA 21-1 levels may be of value
in assessing the response to treatment of patients with lung
cancer. Gaast et al. (1994) reported the value of CYFRA
21-1 for disease monitoring during chemotherapy in 23
patients with squamous cell carcinoma. In their reports.
although there was no comparison with other markers in
terms ofmonitoring, their concordance between the results of
the clinical evaluations according to WHO cnrteria and the
changes in the marker was 65%. The results presented here
from serum CYFRA 21-1 are similar to those previously
reported for various other markers used for monitoring of
response to treatment (Hansen et al.. 1980; Waalkes et al.,
1980; Carney et al.. 1982) in patients with SCLC. However,
in 2 out of 14 patients in whom CYFRA 21-1 was measured
at earlier points in addition to 4-8 weeks there was a
decrease in CYFRA 21-1. indicating a faster excretion of this
marker. We therefore recently conducted a prospective trial
to monitor this marker. In this study CYFRA 21-1 is
measured frequently during the early period after treatment
(including day 1). From this trial we will be able to determine
tumour lysis.
According to McKenzie et al. (1977) the practical value of
a tumour marker depends on three factors: the frequency
with which the marker is detected in the tumour population,
the correlation between the blood level of the marker and the
tumour burden; and the availability of effective treatment for
the tumour. The findings of our study suggest that measure-
ment of CYFRA 21-1 meets these critenra for a tumour
marker of use in screening and planning treatment for
NSCLC.
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